At a glance
- Originator Pharmacia Corporation
- Class Antihyperlipidaemics; Oximes
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 09 Oct 2001 No-Development-Reported for Hypercholesterolaemia in USA (Unknown route)
- 05 Feb 1998 New profile
- 05 Feb 1998 Preclinical development for Hypercholesterolaemia in USA (Unknown route)